Abstracts by key term: Insured care
Drug discount agreements: development, benefits and supply aspects of a successful model
Since the legislator activated the option of drug discount contracts in the GKV Competition Strengthening Act (April 2007), corresponding discount contracts in the generic market segment have developed into a successful model. On the other hand, the objections repeatedly raised by interested parties, in particular pharmaceutical companies, with regard to patient compliance or alleged market share losses of pharmaceutical SMEs, stand up to neither public opinion nor empirical scrutiny. Discount agreements form an efficient and forward-looking competitive instrument between statutory health insurance companies and the pharmaceutical industry.